NICOX (EPA:COX) | WebDisclosure

BRIEF

published on 02/24/2026 at 07:35, 1 month 2 days ago

Nicox dévoile des résultats positifs de phase 3 pour le NCX 470 lors du congrès de l'AGS

Étude De Phase 3 NCX 470 Glaucome Pression Intraoculaire Profil Thérapeutique
BRIEF

published on 02/24/2026 at 07:35, 1 month 2 days ago

Nicox Reveals Positive Phase 3 Results for NCX 470 at AGS Meeting

Glaucoma Phase 3 Study NCX 470 Intraocular Pressure Therapeutic Profile
PRESS RELEASE

published on 02/24/2026 at 07:30, 1 month 2 days ago

Nicox présente des données de Phase 3 positives confirmant le profil thérapeutique de NCX 470 lors du congrès annuel 2026 de l’American Glaucoma Society (AGS)
Nicox présente des données de Phase 3 positives pour NCX 470 au congrès annuel 2026 de l'AGS, démontrant une réduction significative de la pression intraoculaire

Phase 3 Nicox NCX 470 Pression Intraoculaire Congrès AGS
PRESS RELEASE

published on 02/24/2026 at 07:30, 1 month 2 days ago

Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting
Nicox announces positive NCX 470 Phase 3 data on intraocular pressure lowering efficacy at 2026 American Glaucoma Society Annual Meeting

Nicox NCX 470 Phase 3 Data Intraocular Pressure Glaucoma Society
BRIEF

published on 02/16/2026 at 07:35, 1 month 10 days ago

Nicox prépare une soumission de NDA pour NCX 470 après avis positif de la FDA

FDA NDA Nicox NCX 470 Glaucome
BRIEF

published on 02/16/2026 at 07:35, 1 month 10 days ago

Nicox Receives Positive Feedback from FDA for NCX 470 NDA

FDA Nicox Glaucoma Treatment NCX 470 NDA Submission
BRIEF

published on 02/16/2026 at 07:35, 1 month 10 days ago

Nicox reçoit un avis favorable de la FDA concernant sa demande d'autorisation de mise sur le marché (NDA) pour le NCX 470.

FDA Nicox Traitement Du Glaucome NCX 470 Soumission D'un Accord De Confidentialité
BRIEF

published on 02/16/2026 at 07:35, 1 month 10 days ago

Nicox is preparing an NDA submission for NCX 470 following a positive FDA opinion

FDA Glaucoma NDA Nicox NCX 470
PRESS RELEASE

published on 02/16/2026 at 07:30, 1 month 10 days ago

Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470
Nicox receives positive feedback from pre-NDA meeting with U.S. FDA for NCX 470, on track for NDA submission in summer 2026. NCX 470 lowers intraocular pressure in glaucoma patients

FDA Nicox NCX 470 Intraocular Pressure Pre-NDA
PRESS RELEASE

published on 02/16/2026 at 07:30, 1 month 10 days ago

Nicox annonce une réunion pré-NDA positive avec la FDA américaine pour NCX 470
Nicox annonce une réunion pré-NDA positive avec la FDA américaine pour NCX 470, confirmant le dépôt de la NDA pour l'été 2026. Collaboration avec Kowa et avancée vers l'autorisation de mise sur le marché

FDA Nicox NCX 470 Réunion Pré-NDA Autorisation De Marché

Published on 03/26/2026 at 22:05, 23 minutes ago

BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 28 minutes ago

Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 28 minutes ago

Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 1 hour 28 minutes ago

Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/26/2026 at 21:00, 1 hour 28 minutes ago

Rocky Shore Closes Acquisition of Additional Mining Claims

View all ACCESSWIRE

Published on 03/26/2026 at 20:48, 1 hour 40 minutes ago

Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 3 hours 8 minutes ago

Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:13, 3 hours 15 minutes ago

Director Declaration
Published on 03/26/2026 at 19:09, 3 hours 18 minutes ago

2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)
Published on 03/26/2026 at 19:09, 3 hours 18 minutes ago

2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)

View all EQS

Published on 03/26/2026 at 18:17, 4 hours 11 minutes ago

Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 4 hours 11 minutes ago

Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 4 hours 28 minutes ago

Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 4 hours 28 minutes ago

Calendrier financier 2026
Published on 03/26/2026 at 18:00, 4 hours 28 minutes ago

LABORATOIRES EUROMEDIS - Fin du contrat de liquidité

View all LES ECHOS COMFI WIRE

News